Jubilant DraxImage is dedicated to providing radiopharmaceuticals for the diagnosis and treatment of a variety of diseases. We invite you to learn more about these areas and how our products are used by healthcare professionals to care for their patients.
Michael Rossi, R.Ph. has been named President of Jubilant DraxImage as of October 2016. Michael joined Jubilant DraxImage in April 2014, serving as Vice Presidents of Sales, Marketing and Business Operation. He is a proven leader with more than 20 years of experience in the Pharmaceutical Industry focusing on Nuclear Medicine, Imaging, and Medical Devices. Michael held leadership roles with GE Healthcare and Mallinckrodt. He has successfully lead large commercial teams in both North America and abroad. Michael holds a Bachelor of Science Degree in Pharmacy from University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania. Mike was a Board Certified Nuclear Pharmacist for 15 years and is currently a registered pharmacist in the state of Pennsylvania.
With more than twenty years of progressive commercial experience in the specialty pharmaceuticals and targeted medical device markets, Kevin Brooks is a seasoned leader with a strong understanding of business and global radiopharmaceutical market dynamics. Mr. Brooks joins Jubilant DraxImage from Nordion Inc., and GE Healthcare. He has led global-scale marketing and cross-functional brand team initiatives, spearheading the launch of new products and driving successful branding initiatives. Mr. Brooks holds a Bachelor of Health Science from Gwynedd Mercy College, Pennsylvania and a Master of Business Administration from Temple University, Philadelphia, PA as well as being a former Nuclear Medicine Technologist and Medical Sonographer.
Dr. LaFrance, MD, ME, FACP, FACNP, joined Jubilant DraxImage [JDI] in 2012 as Chief Medical Officer [CMO] and VP, Medical & Regulatory Affairs. His broad experience spans over thirty-five years in the practice of medicine, pharmaceutical and healthcare industry including drug research & development and commercialization work with large pharmaceutical, specialty pharmaceutical, molecular imaging and therapeutic companies. Dr. LaFrance has had numerous submitted and approved NDA’s and many additional, successful phase 0-IV programs to his credit. Dr. LaFrance’s experience includes not only North America, but also Europe, Japan, Latin America, Asia and ROW. Important aspects of his responsibilities over the years included identifying, establishing and developing collaborations between industry, government and academia while supporting business development, marketing, and in-licensing objectives through a core of clinical, medical & regulatory affairs expertise. Prior to industry, Dr. LaFrance practiced medicine and held academic faculty appointments at Johns Hopkins University School of Medicine in the Departments of Medicine and Radiology and the Department of Radiological Sciences in the John Hopkins School of Hygiene and Public Health. He is Double Board Certified with Fellowship status both in Internal Medicine and Nuclear Medicine, maintains active Medical Licensure in the United States along with active, professional society membership.
We are pleased to announce the arrival of Ms. Arpita Chatterjee, as Vice-President, Finance, as of April 18, 2016. Arpita joins Jubilant with over 22 years’ experience in finance and accounting. Her main areas of expertise are financial reporting, management of global budgets, interpretation of financial data and staff management. More recently, she worked as Global Director, Finance and Administration for MIP Inc – Montreal. In her new role Arpita will be responsible for the JHS and JDI finance departments. Arpita holds a Bachelor of Commerce and is a member of the CPA.
Dr. Riddoch, B.Sc., Ph.D. has headed the Research and Development group since November 2014 and is responsible for overseeing Jubilant DraxImage’s development pipeline as well as the radiation safety program. Prior to this Dr. Riddoch served in several different positions: Director of Manufacturing Operations (2012-2014), Senior Manager of Research and Development (2011 – 2012) and Senior Scientist (2001 – 2011). Over his career he has been responsible for the development, validation and trouble shooting of many of the products which make up the company’s current Product Portfolio. Dr. Riddoch is an experienced radiochemist, whose research has focused on technetium chelation chemistry and radiohalogen chemistry. He holds an honours B.Sc. and a Ph.D. in Chemistry from McMaster University.
Tara joins Jubilant with over 16 years’ experience in the pharmaceutical industry, including 13 years in quality control, validation and employee management for companies such as Wyeth / Pfizer and TetraGenx. More recently, she worked as Manager, Quality and Validation for Church & Dwight Canada. In her new role Tara will be responsible for the Quality Control and Quality Assurance departments. Tara holds a Bachelor of Science with a specialization in Biochemistry from Concordia University.